logo
Sequel Named as the Official Tampon Partner of the Indiana Fever

Sequel Named as the Official Tampon Partner of the Indiana Fever

Business Wire3 days ago

INDIANAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)-- Sequel has been named as the Official Tampon Partner of the Indiana Fever, it was announced today. As part of the partnership, Sequel products will be available to both Fever players and fans, with complimentary Spiral Tampons available in the team's locker room and throughout Gainbridge Fieldhouse restrooms.
'We are very excited to team up with Sequel, a women-founded and led company that is prioritizing the needs of women athletes,' said Indiana Fever COO and General Manager Amber Cox. 'We are proud to offer free Sequel products to our Fever family, both on the court and off, so they can enjoy the game of basketball with comfort and confidence.'
'Partnering with the Fever means being able to work with the best organization, athletes, and fans in the world right now,' said Sequel co-founder and Chief Executive Officer, Greta Meyer. 'Whether you're on the court or cheering on in the stands, Sequel's goal has always been to be a reliable and trustworthy option, and with this partnership we're getting the chance to do that on one of the biggest stages in women's sports.'
Co-founded by former athletes and engineers Amanda Calabrese and Greta Meyer, Sequel tampons are designed with the athlete in mind. Looking for a period product that fit their active lifestyle and provided better leak protection, the Stanford Cardinal alumnae created their own product, which features helical grooves designed for even absorption.
The game-changing product may be familiar to Fever fans, with guard Lexie Hull also serving as an ambassador for the brand.
About the Indiana Fever:
The Indiana Fever were announced as an expansion franchise in the Women's National Basketball Association (WNBA) in June 1999 and began play during the 2000 season. In 2012, led by Hall of Famer Tamika Catchings, the team won its first WNBA Championship. Today, the team is headlined by some of the league's biggest stars including back-to-back No. 1 overall draft picks Aliyah Boston (2023) and Caitlin Clark (2024), as well as veteran leaders such as Kelsey Mitchell and Natasha Howard.
This season, over the weekend of July 18-19, the Fever will host the 2025 WNBA All-Star Game at Gainbridge Fieldhouse. More information can be found here.
To learn more about the Fever, purchase tickets or join the season ticket waitlist, visit FeverBasketball.com. The team can also be followed across all social media platforms including YouTube, Instagram, Facebook, X, and TikTok.
About Sequel:
Sequel is redefining a critical and stagnant category in women's health, starting with the first reengineered tampon in 80 years. Founded by Stanford product designers and former high-level athletes, the FDA-cleared Sequel Spiral Tampon uses a patented helical design to help prevent leakage and support comfort on and off the field. Sequel is partnering with the best in the sports world to bring the Spiral Tampon to athletes and women everywhere, including Stanford Athletics, Athletes Unlimited, Unrivaled Basketball, DC United, DC Power, and the Indiana Fever. Sequel is backed by top investors in tech, impact, and sports, such as Pear VC, MaC Venture Capital, Cyan Banister and Assia Grazioli.
To learn more and try Sequel visit www.trysequel.com or find us on socials @trysequel on Instagram and TikTok.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson & Johnson's (JNJ) IMAAVY Demonstrates Superior gMG Control
Johnson & Johnson's (JNJ) IMAAVY Demonstrates Superior gMG Control

Yahoo

timean hour ago

  • Yahoo

Johnson & Johnson's (JNJ) IMAAVY Demonstrates Superior gMG Control

Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company's drug, IMAAVY (nipocalimab-aahu), demonstrated consistent and sustained disease control in patients with generalized myasthenia gravis (gMG) compared to other approved FcRn blockers. The findings were presented at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland. Gil C/ According to the findings, IMAAVY showed a comparable onset of symptom relief at Week 1. The drug demonstrated consistent and sustained disease control over multiple timepoints up to 24 weeks. More importantly, IMAAVY showed greater or statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared to the published Phase 3 data of other FcRn blockers. The drug received FDA approval on April 30, 2025, for adults and pediatric patients aged 12 and older with anti-AChR or anti-MuSK antibody-positive gMG. This makes IMAAVY the first and only FcRn blocker approved for both antibody types, covering ≥90% of antibody-positive gMG patients. Johnson & Johnson (NYSE:JNJ) is a global healthcare company. It develops, manufactures, and sells pharmaceuticals and medical devices through two main segments: Innovative Medicine and MedTech. Its key pharmaceutical products include Darzalex, Stelara, Tremfya, and Carvykti, while its MedTech offerings span surgical technologies, orthopedics, and vision care. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer

Yahoo

timean hour ago

  • Yahoo

AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced that the FDA had granted accelerated approval to Datroway for the treatment of adult patients with non-small cell lung cancer (NSCLC). A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The companies signed a global collaboration agreement in July 2020, valued at up to $6 billion. As part of the agreement, Daiichi Sankyo maintains exclusive rights in Japan, while both companies share responsibilities elsewhere. The approval followed a Priority Review and Breakthrough Therapy Designation by the FDA, reflecting the drug's potential to address an unmet medical need. Continued approval may depend on verification of clinical benefit in a confirmatory trial, as is standard for accelerated approvals. Following the approval, AstraZeneca will pay Daiichi Sankyo a $45 million milestone payment for the NSCLC indication, as stipulated in their 2020 collaboration agreement. AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company. It discovers, develops, manufactures, and markets prescription medicines across disease areas like oncology, cardiovascular, renal and metabolism, respiratory, immunology, vaccines, and rare diseases. Its leading products include Tagrisso, Imfinzi, Farxiga, Brilinta, Symbicort, and Soliris. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

Dallas Wings Coach Issues Statement on Paige Bueckers' Injury After Big Game Against Fever
Dallas Wings Coach Issues Statement on Paige Bueckers' Injury After Big Game Against Fever

Yahoo

time3 hours ago

  • Yahoo

Dallas Wings Coach Issues Statement on Paige Bueckers' Injury After Big Game Against Fever

Dallas Wings Coach Issues Statement on Paige Bueckers' Injury After Big Game Against Fever originally appeared on Athlon Sports. Paige Bueckers went off for the Dallas Wings on Friday night, dropping a team-high 27 points on 9-of-18 shooting, with six assists, two steals, two blocks and two triples against the Indiana Fever. Advertisement Unfortunately for Dallas, Bueckers' offensive explosion still wasn't enough to carry them to a victory against a Fever side that was missing the services of the injured Caitlin Clark. In the end, Indiana scored a big road win against the Wings, 94-86. Bueckers, though, ended up on the sidelines on Saturday night as Dallas played in the second night of a back-to-back set. The Wings ruled their star guard out against the Washington Mystics due to a right knee injury. Dallas Wings guard Paige Bueckers is ruled out on Saturday due to a knee Miron-Imagn Images As it turns out, however, Wings fans need not worry about Bueckers' sudden injury absence. Head coach Chris Kolcanes spoke to reporters before the Mystics game and revealed that the issue is not serious. Advertisement "Just precautionary, some soreness," Kolcanes said, via Joey Mistretta of ClutchPoints. "Just doing our due diligence and managing what's best for her long-term health." Bueckers' absence from the Mystics game came as a bit of a surprise, considering how she looked perfectly fine against Indiana. Based on Kolcanes' statement, it appears that the decision to have her sit out on Saturday involved wanting to give the No. 1 overall pick some rest on the second night of a back-to-back. As such, barring any unforeseen setbacks, Bueckers should be back in action in Dallas' next game, which will be on Thursday against the Phoenix Mercury. Related: Dallas Wings Make Decision After Unwanted Paige Bueckers Situation Related: Fever Coach Stephanie White Issues Apology After Caitlin Clark Decision Related: Former Fever Player Reveals Striking Similarity Between Caitlin Clark and Paige Bueckers This story was originally reported by Athlon Sports on Jun 29, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store